葛兰素史克盘前涨超2%在日本获得支气管哮喘治疗的监管批准

动脉网01-06

葛兰素史克1月6日盘前股价涨超2%，报50.08美元。消息面上，其用于治疗支气管哮喘及伴鼻息肉慢性鼻窦炎的药物Exdensur（通用名：depemokimab）在日本获得监管批准。该药物此前已在美国和英国获批上市，目前正在包括中国在内的其他多个市场接受监管审查。此次日本获批，意味着葛兰素史克在拓展Exdensur市场方面取得新进展，不仅为日本当地支气管哮喘及伴鼻息肉慢性鼻窦炎患者带来新治疗选择，也...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2601954658?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-06 17:28","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2601954658","market":"us","top_or_hot":-1,"title":"葛兰素史克盘前涨超2%在日本获得支气管哮喘治疗的监管批准","media":"动脉网","content":"<div>\n<p>葛兰素史克1月6日盘前股价涨超2%，报50.08美元。消息面上，其用于治疗支气管哮喘及伴鼻息肉慢性鼻窦炎的药物Exdensur（通用名：depemokimab）在日本获得监管批准。该药物此前已在美国和英国获批上市，目前正在包括中国在内的其他多个市场接受监管审查。此次日本获批，意味着葛兰素史克在拓展Exdensur市场方面取得新进展，不仅为日本当地支气管哮喘及伴鼻息肉慢性鼻窦炎患者带来新治疗选择，也...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106173839a6f9cef6&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>葛兰素史克盘前涨超2%在日本获得支气管哮喘治疗的监管批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n葛兰素史克盘前涨超2%在日本获得支气管哮喘治疗的监管批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-06 17:28 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106173839a6f9cef6&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>葛兰素史克1月6日盘前股价涨超2%，报50.08美元。消息面上，其用于治疗支气管哮喘及伴鼻息肉慢性鼻窦炎的药物Exdensur（通用名：depemokimab）在日本获得监管批准。该药物此前已在美国和英国获批上市，目前正在包括中国在内的其他多个市场接受监管审查。此次日本获批，意味着葛兰素史克在拓展Exdensur市场方面取得新进展，不仅为日本当地支气管哮喘及伴鼻息肉慢性鼻窦炎患者带来新治疗选择，也...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106173839a6f9cef6&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1829250122.USD","symbol_name":"高盛欧洲核心股票组合Acc","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106173839a6f9cef6&s=b","article_id":"2601954658","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106173839a6f9cef6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2601954658","pubTimestamp":1767691680,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"葛兰素史克1月6日盘前股价涨超2%，报50.08美元。消息面上，其用于治疗支气管哮喘及伴鼻息肉慢性鼻窦炎的药物Exdensur（通用名：depemokimab）在日本获得监管批准。该药物此前已在美国和英国获批上市，目前正在包括中国在内的其他多个市场接受监管审查。此次日本获批，意味着葛兰素史克在拓展Exdensur市场方面取得新进展，不仅为日本当地支气管哮喘及伴鼻息肉慢性鼻窦炎患者带来新治疗选择，也进一步巩固了葛兰素史克在全球制药领域的地位，后续该药物在其他市场的审查结果也备受关注。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4007":"制药","BK4588":"碎股","GSK.UK":"葛兰素史克","GSK":"葛兰素史克","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓"},"translate_title":"GlaxoSmithKline rose more than 2% premarket to obtain regulatory approval for bronchial asthma treatment in Japan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK.UK":0.6,"GSK":1.5},"content_text":"葛兰素史克1月6日盘前股价涨超2%，报50.08美元。消息面上，其用于治疗支气管哮喘及伴鼻息肉慢性鼻窦炎的药物Exdensur（通用名：depemokimab）在日本获得监管批准。该药物此前已在美国和英国获批上市，目前正在包括中国在内的其他多个市场接受监管审查。此次日本获批，意味着葛兰素史克在拓展Exdensur市场方面取得新进展，不仅为日本当地支气管哮喘及伴鼻息肉慢性鼻窦炎患者带来新治疗选择，也进一步巩固了葛兰素史克在全球制药领域的地位，后续该药物在其他市场的审查结果也备受关注。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601954658","isCrawlerRequest":true}